| Literature DB >> 19381328 |
Rebecca M Turner, David J Spiegelhalter, Gordon C S Smith, Simon G Thompson.
Abstract
Policy decisions often require synthesis of evidence from multiple sources, and the source studies typically vary in rigour and in relevance to the target question. We present simple methods of allowing for differences in rigour (or lack of internal bias) and relevance (or lack of external bias) in evidence synthesis. The methods are developed in the context of reanalysing a UK National Institute for Clinical Excellence technology appraisal in antenatal care, which includes eight comparative studies. Many were historically controlled, only one was a randomized trial and doses, populations and outcomes varied between studies and differed from the target UK setting. Using elicited opinion, we construct prior distributions to represent the biases in each study and perform a bias-adjusted meta-analysis. Adjustment had the effect of shifting the combined estimate away from the null by approximately 10%, and the variance of the combined estimate was almost tripled. Our generic bias modelling approach allows decisions to be based on all available evidence, with less rigorous or less relevant studies downweighted by using computationally simple methods.Entities:
Year: 2009 PMID: 19381328 PMCID: PMC2667303 DOI: 10.1111/j.1467-985X.2008.00547.x
Source DB: PubMed Journal: J R Stat Soc Ser A Stat Soc ISSN: 0964-1998 Impact factor: 2.483
Fig. 1Identifying internal and external biases
Checklist for sources of internal bias†
| Subjects in different intervention groups recruited from same populations? | ||
| Subjects in different intervention groups recruited over same time periods? | ||
| Inclusion and exclusion criteria clear? | ||
| Randomization used? | ||
| Adequate allocation concealment? | ||
| Comparable baseline characteristics? | ||
| Adequate adjustment for confounding? [In observational studies only] | ||
| Does extent of | ||
| Subjects blinded? | ||
| Care givers blinded? | ||
| Did subjects receive their assigned (or reputedly received) interventions? | ||
| Does extent of | ||
| Are the results unlikely to be affected by losses to follow-up? | ||
| Are the results unlikely to be affected by | ||
| Does extent of | ||
| Outcome assessors blinded? | ||
| Outcome measured accurately? | ||
| If the results were back-calculated from a reported analysis, was the statistical analysis appropriate? | ||
| Does extent of | ||
| Does extent of | ||
†The empty areas are to be completed.
Checklist for sources of external bias†
| Study subjects in idealized study drawn from population identical to target population, with respect to age, sex, health status etc.? | ||
| Does extent of | ||
| Active intervention in idealized study identical to target active intervention in dose, timing etc.? | ||
| Does extent of | ||
| Control intervention in idealized study identical to target control intervention? | ||
| Does extent of | ||
| Study outcome for idealized study identical to target outcome? | ||
| Does extent of | ||
†The empty areas are to be completed.
Fig. 2Elicitation scale for quantifying additive bias
Fig. 3Effect of ranges for bias on the approximate width of the CI for the bias-adjusted log-odds-ratio, assuming rare events and no intervention effect (ranges refer to a symmetric relative risk scale, as shown in Fig. 2): , no bias; , 67% range (0.9, 0.9); , 67% range (0.7, 0.7); 67% range (0.5, 0.5)
Studies of the effectiveness of anti-D prophylaxis for prevention of postnatal sensitization in Rhesus negative women
| Bowman | Non-randomized, historical controls | Unsensitized pregnant Rhesus negative women | 1500 IUs at 28 and 34 weeks | Sensitization during pregnancy or within 3 days of delivery | 0/1357 | 62/3533 | −3.89 | 2.02 |
| Non-randomized, historical controls | Unsensitized pregnant Rhesus negative women | 1250 IUs at 32–34 weeks | Sensitization at 8 months | 2/529 | 10/645 | −1.42 | 0.60 | |
| Quasi-randomized study (allocation based on year of birth) | Pregnant Rhesus negative | 500 IUs at 28 and 34 weeks | Sensitization at 2–12 months | 1/472 | 7/468 | −1.97 | 1.15 | |
| Randomized trial | Rhesus negative | 250 IUs at 28 and 34 weeks | Sensitization at 6 months | 3/361 | 6/405 | −0.58 | 0.51 | |
| Non-randomized, contemporary controls | Rhesus negative unsensitized | 500 IUs at 28 and 34 weeks | Sensitization in a subsequent pregnancy | 12/3320 | 26/3146 | −0.83 | 0.12 | |
| Non-randomized, historical controls | Rhesus negative | 500 IUs at 28 and 34 weeks | Sensitization in a subsequent pregnancy | 4/1425 | 16/1426 | −1.39 | 0.31 | |
| Non-randomized, historical controls | Rhesus negative | 500 IUs at 28 and 34 weeks | Sensitization in a subsequent pregnancy | 2/325 | 22/582 | −1.85 | 0.55 | |
| Non-randomized, historical controls | Unsensitized pregnant Rhesus negative women | 1500 IUs at 28 weeks | Sensitization at 10 months | 0/291 | 6/322 | −2.48 | 2.16 | |
Primipara: a woman who has given birth for the first time to an infant or infants, alive or stillborn (after 20 weeks’ gestation).
Primigravida: a woman who is pregnant for the first time.
Parameters of NICE target question and idealized version of Hermann
| Population | Unsensitized pregnant Rhesus negative women in the UK | Unsensitized Rhesus negative women delivered of Rhesus positive babies at the Växjö hospital in Sweden |
| Intervention | Dose of 500 IUs anti-D immunoglobulin offered at 28 and 34 weeks’ gestation, in addition to control antenatal care | Dose of 1250 IUs anti-D immunoglobulin given at 32–34 weeks’ gestation, in addition to control antenatal care |
| Control | Anti-D immunoglobulin offered | Anti-D immunoglobulin offered |
| Outcome | Rhesus sensitization which will affect a subsequent pregnancy | Rhesus sensitization at 8 months |
Fig. 4Additive biases in Hermann , 67% ranges of distributions elicited from four assessors (A–D) and means and 67% ranges for total additive bias
Fig. 5Effect of adjusting for (a) additive bias and (b) all bias on the odds ratio (with 95% CIs) in Hermann
Summary of results for Hermann and for meta-analysis of eight anti-D immunoglobulin studies, before and after adjusting for biases: estimated odds ratio of sensitization, comparing routine anti-D immunoglobulin against control, and corresponding ‘effective number of events’ in each arm†
| None | 0.24 (0.05, 1.10) | 2.1 | 8.5 | 0.28 (0.17, 0.46) | 19.7 | 70.8 | 0.05 |
| Additive biases | 0.39 (0.05, 3.04) | 1.3 | 3.3 | 0.29 (0.14, 0.57) | 10.4 | 36.1 | 00 |
| All biases | 0.37 (0.03, 4.68) | 0.8 | 2.2 | 0.25 (0.11, 0.56) | 7.0 | 28.5 | 00 |
Details are given in Section 5.2.
Fig. 6Meta-analysis of eight studies evaluating the effectiveness of routine anti-D prophylaxis—unadjusted and bias-adjusted odds ratios (with 95% CIs) (for each result, the corresponding total ‘effective number of events’ is listed alongside): (a) unadjusted; (b) bias adjusted (additive); (c) bias adjusted (all)
Fig. 7Elicitation scale for quantifying proportional bias
Fig. 8Proportional biases in Hermann , 67% ranges of distributions elicited from four assessors (A–D) and means and 67% ranges for total internal and external proportional bias
Fig. 9Meta-analysis of anti-D immunoglobulin studies adjusted for additive and proportional biases, using the elicited opinions of assessors (a) A, (b) B, (c) C and (d) D separately (with 95% CIs)